Life X Ventures

Life X Ventures backs early-stage companies that can measurably extend the healthy human lifespan. The firm targets technical founders working at the convergence of artificial intelligence, computational biology, and digital health delivery. Its thesis rejects the distinction between 'healthcare' and 'climate' investments, viewing environmental resilience as a direct input to population-level longevity.

Investment decisions are led by Founder and Managing Partner Fady Yacoub alongside Co-Founder and General Partner Gaurav Gupta. Both principals are active on the boards of portfolio companies and maintain direct involvement in sourcing, diligence, and portfolio support. The firm operates without a large investment committee layer, keeping decision-making concentrated with the founding partners.

The firm targets pre-seed through Series A rounds, with capital reserved for selective follow-on investments in portfolio companies that reach technical and commercial milestones. Its primary entry point is the first institutional round, often leading or co-leading alongside other deep-tech specialist funds. Later-stage participation is rare and occurs only when the firm holds board seats from earlier rounds.

The firm sources heavily from academic research institutions, including Stanford, MIT, and several European technical universities known for biotechnology and AI programs. It maintains scouting relationships across North America, Western Europe, and Israel. Its partners cultivate founder relationships at the preprint and lab-spinout stage, often engaging 12 to 18 months before a company raises institutional capital.

No. Life X Ventures explicitly avoids traditional biotech models that depend on single-asset FDA pathways and large-scale clinical trial infrastructure. Instead, it backs platform companies whose technology layers — machine-learning for molecule discovery, decentralized diagnostic hardware, or software-defined metabolic interventions — can produce returns without binary regulatory outcomes on a single compound.